Artificial intelligence (AI) has the potential to revolutionize drug development through improved efficiency, accuracy, and speed. However, research indicates that biopharma companies have been slow in using AI and digital technologies compared to other industries.

This article explores the key considerations in using AI, application areas in biopharma, and how leading CRO/CDMO Syngene uses AI and digital technologies to accelerate drug discovery, development, and manufacturing for its clients.

Among the proprietary tools and technologies Syngene has introduced, are SynSight™, a voluntary data consortium to share anonymized data for predictive modeling,  SynAI™  to identify and prioritize disease targets faster,  SARchitect™ for data visualization and analytics, and so on. Syngene also leverages AI to enhance project management, compound storage, and supply chain efficiency, moving toward a fully digitized and automated ecosystem.